
FDA expands gene therapy use in Duchenne muscular dystrophy
The US Food and Drug Administration (FDA) has expanded its approval for Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least four years of age. Confirming the functional benefits, the FDA granted traditional approval for ambulatory… Read More





